Regeneron (REGN) shares jump after third-quarter revenue rose 36% and non-GAAP EPS rose 70%
FROM THE WIRE · FINANCE.YAHOO.COM
Regeneron (REGN) stock trades up, here is why What happened? Shares of biotech company Regeneron (NASDAQ:REGN) jumped 11.5% in the afternoon session after the company reported a 36% increase in third-quarter 2026 revenue to $5.1 billion, alongside a 70% rise in non-GAAP diluted…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishStrong quarterly results for a large biotech drove an 11.5% afternoon share jump, making the report relevant for the sector.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Regeneron reported third-quarter 2026 revenue of 5.1 billion dollars, up 36%.
- 02Non-GAAP diluted earnings per share rose 70% to 20.07 dollars.
- 03Record net sales were reported for Dupixent, EYLEA HD and Libtayo.
- 04The company widened its Sanofi alliance and expects an FDA decision on cemdisiran in November.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Regeneron Pharmaceuticals, Inc.927.89 USDMarket closedtoday +13.33%Positive Sanofi44.34 USDMarket closedtoday +2.81%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets